We provide answers, so you can focus on care
We’re moving exome and genome from specialized tests to standard of care, improving patients’ lives by building towards a future where we can sequence DNA once and analyze the results for a lifetime.
We’re a leader in genomics, with over 400,000 clinical exome and genome tests interpreted and delivered. We offer premier expertise in exome sequencing for pediatric conditions and rare and ultra-rare genetic diseases.
Centrellis®, our proprietary health intelligence platform, integrates digital tools with artificial intelligence, allowing us to ingest and synthesize clinical and genomic data to deliver better health insights.
With one of the world’s largest rare disease data sets, we’re poised to accelerate the use of genomics and leverage large-scale clinical data to enable precision medicine as the standard of care.
GeneDx to Participate in Upcoming Investor Conferences in June
May 24, 2023
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that management will participate at the following investor conferences in June
GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations
May 23, 2023
Keynote session to highlight value of GeneDx genomic data and clinical insights to accelerate genetic neurodevelopmental disorder pipeline for Mahzi Therapeutics
GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 22, 2023
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it had received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that, because the Company’s Class A common stock had a closing bid price at or above $1.00 per share